Imprimis Pharmaceuticals (NASDAQ: IMMY) is a specialty pharmaceutical company focused on the development, production and dispensing of novel compounded pharmaceuticals. The company’s two business programs, Imprimis Cares™ and Custom Compounding Choice™, focus on patient outcomes and affordability by offering high quality custom compounded drugs in all 50 states. Imprimis expects to use its proprietary drug delivery technology, coupled with licensed technologies, and proprietary formulations and market data, to identify pharmaceutical development opportunities where there is a significant unmet need for a new drug product. For more information, visit the company’s website at www.imprimispharma.com.